Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure-Reference-Cited by-同舟云学术

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure

Published:2021-03-30 Issue:8 Volume:60 Page:1061-1071
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Nabeta Takeru,Kida Keisuke,Ishida Miwa,Shiono Takaaki,Suzuki Norio,Doi Shunichi,Tsukahara Maya,Ohta Yuki,Kimura Tetsuya,Yamaguchi Keita,Takita Atsushi,Matsumoto Naoki,Akashi Yoshihiro J.,Ako Junya,Inomata Takayuki

Funder

Daiichi Sankyo Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-021-00999-y.pdf

Reference33 articles.

1. Shiga T, Suzuki A, Haruta S, Mori F, Ota Y, Yagi M, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. ESC Heart Fail. 2019;6(3):475–86.

2. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11.

3. Fujii N, Naito K, Nakahara N, Nakano A, Takagi S. Clinical characteristics and outcomes in super-elderly patients (>85 years) with heart failure: single center observational study in Japan. Acute Med Surg. 2014;1(2):76–82.

4. Horiuchi Y, Tanimoto S, Latif A, Urayama KY, Aoki J, Yahagi K, et al. Identifying novel phenotypes of acute heart failure using cluster analysis of clinical variables. Int J Cardiol. 2018;262:57–63.

5. Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, et al. Acute decompensated heart failure syndromes (ATTEND) registry: a prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159(6):949-55.e1.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study;Frontiers in Cardiovascular Medicine;2022-12-22

2. Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: The impact of plasma concentration on clinical outcomes;Thrombosis Research;2022-10

3. Associations among plasma concentrations of edoxaban and M-4, prothrombin time, and the SLCO1B1*15 haplotype in patients with non-valvular atrial fibrillation;Therapeutic Drug Monitoring;2022-09-23

4. D-dimer levels in patients with nonvalvular atrial fibrillation and acute heart failure treated with edoxaban;Journal of Cardiology;2022-06